Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Regeneron joins Lilly in validating the Covid antibody approach
Like Lilly Regeneron reports promising but not emphatic data with its antibody treatment, and the question turns to approvability.
J&J and Novavax push Covid-19 vaccine candidates into late-stage testing
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
Healthineers collaboration aims to link antibodies to immunity
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Lilly leads the Covid antibody charge
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Regeneron joins Lilly in validating the Covid antibody approach
Like Lilly Regeneron reports promising but not emphatic data with its antibody treatment, and the question turns to approvability.
J&J and Novavax push Covid-19 vaccine candidates into late-stage testing
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
Healthineers collaboration aims to link antibodies to immunity
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Lilly leads the Covid antibody charge
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
